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AbstrAct
Ovarian clear cell carcinoma (OCCC) constitutes one of the subtypes of ovarian 
cancers, but it has unique clinical, histological and biological characteristics, one 
of which is chemo-resistance. It is also known to develop from endometriotic cyst, 
a benign ovarian tumor, at relatively high frequency. Recently, it is becoming well 
known that most of OCCCs express HNF1β, a transcription factor, which is closely 
associated with the development of liver, pancreas and kidney, as well as occurrence 
of familial forms of type 2 diabetes. Expression of HNF1β is now regarded as a 
hallmark of this tumor. Nevertheless, exact biological function of this gene in OCCC 
has not been clarified. We have shown in previous studies that microenvironment in 
endometriotic cysts contains severe oxidative stress and OCCC develops under such 
stressful environment as stress-resistant tumor, which may lead to chemo-resistance. 
We also showed that increased expression of HNF1β facilitates glucose uptake and 
glycolysis, which is known as Warburg effect. In the previous issue of this journal, by 
using comprehensive metabolome analysis, we report that HNF1β actually reduces 
and protects themselves from internal oxidative stress by dramatically changing 
cellular metabolism. In this article, we review the relevance and significance of 
cancer-specific metabolism and how they are associated with biological characteristics 
of OCCC via expression of HNF1β, along with future clinical implications of targeting 
cancer-specific metabolism.
IntroductIon
Ovarian clear cell carcinoma (OCCC) has recently 
been considered as a distinct entity among epithelial 
ovarian cancers. While a majority of the epithelial cancers 
are relatively sensitive to chemotherapy, OCCCs are 
mostly chemo-resistant [1-4], and a novel therapeutic 
approach is urgently desired. Other notable features 
that distinguish this tumor from other subtypes includes 
frequent occurrence in endometriotic cysts, relatively slow 
growth, and frequent complication of thromboembolism 
[4-7]. In particular, the vast majority of cancers arising in 
endometriotic cysts are either clear cell or endometrioid 
subtype, suggesting that a unique carcinogenic process is 
involved [8-10]. 
Nevertheless, the underlying mechanisms to explain 
the uniqueness of OCCC are not fully understood, partly 
because specific genetic events associated with OCCC 
had not been clarified. However, recently, genetic events 
including the ARID1A mutation [11-13], activation of the 
PIK3A mutations [14, 15] and hepatocyte nuclear factor 
1β (HNF1β) overexpression [16-18] have been linked 
to OCCC. We have been continuously investigating the 
causal relationship between the microenvironment in the 
endometriotic cyst and the occurrence of OCCC from 
various viewpoints [8, 10, 19, 20]. Recently, we have 
shown that HNF1β overexpression significantly influences 
the metabolic activity of OCCC, which is distinct from that 
of other ovarian cancers [21]. It has also been suggested 
that altered metabolism caused by HNF1β overexpression 
Oncotarget30705www.impactjournals.com/oncotarget
in OCCC is responsible for some of the biological features 
of OCCC [22]. In this review, we provide an overview 
of cancer-specific metabolism, discuss how they play 
important roles in OCCC, and possible future direction of 
metabolism-targeted cancer therapy. 
MAlIgnAnt tuMor exhIbIts unIque 
MetAbolIsM, cAlled WArburg 
effect
It has long been recognized that cancer cells have 
unique, somehow curious metabolic features. In 1924, Otto 
Warburg reported that cancer cells, unlike most normal 
cells, prefer to metabolize glucose by glycolysis rather 
than oxidative phosphorylation, even in the presence of a 
sufficient oxygen supply that enables cells to perform the 
latter [22, 23]. Energy production by glycolysis is far less 
efficient than by oxidative phosphorylation; only 2 ATPs 
per glucose versus 36 ATPs, respectively, are required 
[23]. This paradoxical phenomenon is called the “the 
Warburg effect”. The Warburg effect, which is manifested 
by increased glucose consumption, decreased oxidative 
phosphorylation and accompanying lactate production, has 
been confirmed and is generally accepted as it has been 
demonstrated in various tumors. It is presently considered 
to be a metabolic hallmark of cancer [24-26]. This nature 
of cancers is clinically used as FDG-PET (F-fluoro-
2-deoxy-D glucose positron emission tomography) in 
various cancers including ovarian cancer. It has been 
reported that tumor metabolic activity is associated with 
prognosis of the patient with ovarian cancers in general 
[27] and OCCC [28], although the latter was reported to 
have lower FDG uptake compared with serous ovarian 
cancers [29]. However, the causal mechanism and 
implication for cancer biology still remains unclear. 
Recently, several mechanisms have been proposed 
for the altered metabolism in cancer cells. First, specific 
genetic events were linked to the change in their 
metabolic status. In glioblastoma cells, inhibition of 
H-Ras resulted in diminished glycolysis and cell death 
[30]. The oncogenic molecule Akt also stimulates aerobic 
glycolysis in cancer cells [31]. C-Myc potently enhances 
the glycolytic pathway, increasing target gene expression 
from glucose transporters through pyruvate kinase 
[32, 33]. Mutation of the p53 tumor suppressor causes 
increased glucose consumption by enhancing the pentose 
phosphate pathway [34]. Therefore, transformation 
caused by oncogenes often accompanies the alteration of 
glucose metabolism. Second, the tumor microenvironment 
sometimes provides pressure for metabolic change, as 
shown in next section. 
MIcroenvIronMent-AssocIAted 
gene InductIon In occc Includes 
HNF1β
It is clinically well known that OCCC arises 
predominantly from ovarian endometriotic cyst, which 
is characterized by repeated bleeding into the cyst cavity 
during the menstrual cycle [10]. We have shown that the 
content of an endometriotic cyst, consisting of old blood, 
which contains a markedly high concentration of free 
iron compared with other benign ovarian cysts [19]. Free 
iron is a source of reactive oxygen species (ROS) and is 
associated with cancer development through the induction 
of persistent oxidative stress in several organs, such as 
the liver and lung [35-37]. In fact, we have found that the 
level of oxidative stress and the extent of DNA damage 
were significantly elevated in endometriotic cysts [19]. 
These data indicate that 1) extensive oxidative stress in the 
endometriotic cyst may contributes to high incidence of 
cancer occurrence (Figure 1), and endometriotic epithelial 
cells which are exposed to extensive oxidative stress must 
cope with it to survive. 
To further investigate the role of microenvironment 
in OCCC, we employed comprehensive gene-expression 
analyses. Microarray analysis identified a gene signature 
that distinguishes clear cell carcinoma from other types 
of ovarian cancer, which we designated as the ovarian 
clear cell carcinoma signature (OCCC signature) [20]. 
Importantly, the OCCC signature was induced when 
ovarian epithelial cells were exposed to the contents 
of endometriotic cysts, implying that it is originally 
driven by the unique microenvironment. A categorical 
analysis demonstrated that the OCCC signature is mainly 
comprised of genes belonging to three categories, stress 
response, sugar metabolism and coagulation, suggesting 
that these three entities define the biological identity of 
OCCC. 
Among the genes included in the OCCC signature, 
we focused on HNF1β for the following reasons. First, 
HNF1β is overexpressed in the majority of OCCC. 
[16-18]. Due to its sensitivity and specificity, HNF1β 
overexpression is regarded as a hallmark of OCCC among 
epithelial ovarian cancers. Second, we have shown that 
the expression of HNF1β is epigenetically regulated [20, 
38, 39]. In comparison of methylation profiles between 
OCCC and non-clear cell ovarian cancers, a majority of 
the OCCC-specific hypomethylated genes were shown to 
have HNF1-binding sites. Third, a pathway analysis of 
the OCCC signature suggested that HNF1β is a central 
mediator of the OCCC-specific signaling network [20]. 
Finally, a motif analysis revealed that HNF1 binding 
motifs are significantly enriched in genes that comprise 
the OCCC signature [18]. Collectively, we assumed that 
HNF1β plays a central role in the manifestation of the 
unique biological phenotype of OCCC. 
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HNF1β is a key Factor botH iN 
orgAn developMent And cAncer 
occurrence
HNF1β is a multifunctional transcription factor 
that shares strong homology with HNF1α and regulates 
wide variety of gene expressions [40]. It is especially 
associated with the developmental process of important 
organs. HNF1 genes were originally identified as genes 
preferentially expressed in hepatocytes, and the lack of 
HNF1β lead to defective hepatic bud formation [41]. 
Additionally, the lack of HNF1β in mice leads to pancreas 
agenesis [42]. Maestro et al. suggested that HNF1β is a 
regulator of pancreas organogenesis and differentiation 
[43]. HNF1β was also shown to be essential for nephron 
segmentation during nephrogenesis [44]. Clinically, 
heterozygous germline mutations in HNF1β cause 
familial forms of type 2 diabetes called as maturity-onset 
diabetes of the young, subtype 5 (MODY5), which is 
frequently associated with congenital abnormalities, such 
as polycystic kidney, pancreatic hypoplasia and genital 
tract abnormality [45-47]. Mutations of HNF1β may 
also be responsible for some sporadic congenital renal 
abnormalities [48]. In adulthood homeostasis, HNF1β was 
shown to play a crucial role in renal repair after ischemia/
reperfusion in the acute kidney injury model [49, 50]. 
Contrary to the developmental stage in which 
HNF1β defect influences normal organ development, 
overexpression of HNF1β has been reported in multiple 
malignancies. As stated above, it is specifically expressed 
in OCCC among ovarian cancers [16-18]. In addition, 
HNF1β may play an important role in prostate and 
hepatocellular carcinomas [51-53]. However, the precise 
mechanism of how HNF1β contributes to cancer biology 
remains unclear. So far, the reported function of HNF1β 
includes epithelial morphogenesis and differentiation [54, 
55], regulation of the urate transporter and organic anion 
transporters [56, 57], and the metabolic regulation and 
ROS reduction discussed here. 
HNF1β drastically alters 
glycolytic process iN occc cells
The importance of the metabolic aspect of OCCC 
was predicted as stated above. In addition, there was 
growing evidence suggesting that HNF1β is associated 
with glucose metabolism. Balakrishnan et al. and our 
group reported that HNF1β induces sodium-glucose co-
transporter and glucose transporter 1, respectively [21, 
58]. Senkel et al. identified 25 target genes of HNF1β 
in a human embryonic kidney cell line, which includes 
dipeptidyl peptidase 4 (DPP4), which is known to play 
a major role in glucose metabolism [59]. Gregori et al. 
found that the expression of aldolase B, an enzyme that is 
figure 1: possible contribution of unique microenvironment in endometriotic cyst to the frequent development of 
ovarian cancer. Microenvironment, especially high concentration of free iron, which derived from old blood accumulated in the cyst, 
causes oxidative stress (ROS), and causes DNA damage. Accumulation of DNA damage over the years eventually leads to the cancer 
development. 
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involved in two opposite metabolic pathways, glycolysis 
and gluconeogenesis, is controlled by the two HNF1 
binding sites in the enhancer [60].
Actually, we noticed a functional link between 
HNF1β and cell metabolism in our own experiments 
[21]. We knocked down the expression of HNF1β by 
shRNA in RMG2 human OCCC cells, which originally 
has high expression of HNF1β. Then, we found that the 
growth of HNF1β-high original RMG2 was slower than 
HNF1β_knockdown RMG2. Nevertheless, we noticed 
that the color of the media in HNF1β-high original RMG2 
tended to be yellow compared to the HNF1β_knockdown 
RMG2, leading to the finding that lactic acid accumulates 
more in the former. These results suggest that HNF1β-high 
RMG2 exhibited higher glucose metabolism, but it was 
not the consequence of rapid cell proliferation [21]. We 
further elucidated this seemingly curious phenomenon 
in detail, and we found that glucose uptake, as well as 
glycolysis, is significantly higher in HNF1β-high RMG2. 
These metabolic changes are consistent with “the Warburg 
effect”. However, the biological influence, perhaps an 
advantageous influence, of such metabolic alteration for 
OCCC cells remained unclear. It was not likely that higher 
glucose uptake directly contributed to cell proliferation, as 
stated above. 
To explore the intracellular metabolic change 
triggered by HNF1β expression, in the study in this issue 
of journal, we performed a comprehensive metabolite 
analysis (the metabolome assay) between HNF1β-high 
RMG2 and HNF1β_knockdown RMG2 cells [61]. As 
expected, repression of HNF1β expression caused drastic 
intracellular metabolic alteration. The most prominent 
alteration is the increase in glycolysis and, on the other 
hand, the decrease in oxidative phosphorylation. Because 
this shift is the main component of the Warburg effect, we 
can say that HNF1β enhances the Warburg effect in OCCC 
cells. One question remains: why (for what purpose) do 
OCCC cells employ such metabolic activity? To answer 
this question, I will next discuss the biological aspect of 
the Warburg effect. 
bIologIcAl Aspect of the WArburg 
eFFect aNd tHe role oF HNF1β
Since Warburg first reported unique cancer 
metabolism, a number of researchers have tried to explain 
how it contributes to cancer biology. Warburg himself 
already noticed that this metabolic reprograming does 
not simply enable cancer cells to live under hypoxic 
conditions because the Warburg effect is also observed 
in the environment with abundant oxygen. He speculated 
that mitochondrial dysfunction in cancer cells hampers 
oxidative phosphorylation and forced them to switch to 
glycolysis [62]. However, recent studies have revealed 
that many cancers do not necessarily have mitochondrial 
defects [23], or mitochondrial dysfunction does not always 
linked to Warburg effect [63]. The apparent advantage of 
energy production by glycolysis is that, if cancer cells have 
a sufficient glucose supply available, they can produce 
energy more quickly by glycolysis than by oxidative 
phosphorylation even under normoxic conditions. 
Moreover, glycolysis can support cell proliferation in 
other processes, supplying substances such as nucleotides, 
amino acids and lipids for biosynthesis. In term of material 
supply for cell growth, glycolysis is more efficient than 
oxidative phosphorylation [64-66]. 
In addition to supporting cell proliferation, the 
metabolism shift from oxidative phosphorylation to 
aerobic glycolysis confers another important advantage for 
cancer cells, namely, cell survival [66, 67]. Suppression 
of oxidative phosphorylation compromises intrinsic 
apoptosis through inhibition of proapoptotic proteins, Bax 
and Bak, and through reduction of ROS production in 
mitochondria. From this viewpoint, we analyzed the whole 
metabolic process in HNF1β-high and low RMG2 cells, 
and obtained several notable findings [61]. First, we could 
not detect any findings that HNF1β-induced metabolic 
change contributes to cell proliferation. Second, neither 
energy nor biomass production seemed augmented in 
HNF1β-high RMG2. Actually, these were in accordance 
with the fact that HNF1β_knockdown RMG2 grow 
more rapidly than HNF1β-high RMG2, as mentioned 
earlier. Clinically, OCCC is known as a relatively slow-
growing tumor, which may explain why it does not receive 
growth benefit from the Warburg effect. Third, survival 
of HNF1β-high RMG2 was significantly better compared 
with HNF1β_knockdown RMG2 especially under hypoxic 
conditions. Furthermore, these cells were more resistant 
to CDDP treatment in hypoxic conditions compared with 
HNF1β_knockdown RMG2. Most importantly, survival 
benefit of HNF1β-high RMG2 was significantly impaired 
in low glucose conditions, suggesting that cell survival of 
HNF1β-high RMG2 is highly dependent of glucose uptake 
and consumption. 
We then measured intracellular ROS activity in 
these cells, which indicated that HNF1β-high RMG2 had 
lower levels of intracellular ROS. When these cells were 
exposed to known extracellular oxidative stressors such 
as ferric nitrilotriacetate (FeNTA) or H2O2, HNF1β-high 
RMG2 had lower ROS activity levels compared with their 
HNF1β_knockdown counterparts [61]. 
These data collectively suggest that, HNF1β reduces 
oxidative phosphorylation, which is the primary source of 
intracellular ROS, by increasing the oxygen-independent 
glycolysis, and confers ROS resistance in OCCC cells. 
Therefore, in this particular case, the Warburg effect 
primarily contributes cell survival, rather than cell 
proliferation. Thus, the Warburg effect, which represents 
frequently observed metabolic alterations in cancers, may 
comprise of different mechanisms with different biological 
consequence according to the cancer types and their 
requirements. 
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HNF1β coNFers ros resistaNce by 
MultIple MechAnIsMs
In addition to the findings above, our study 
revealed that HNF1β also contributes ROS reduction 
with mechanisms other than the Warburg effect [61]. 
HNF1β-high RMG2 had significantly higher activity of 
intracellular GSH, a major regulator of intracellular ROS. 
Furthermore, rBAT, a cystine transporter, was expressed 
at significantly higher levels in these cells. Knockdown 
of rBAT by sh-RNA resulted in decreased levels of 
intracellular GSH and increased ROS activity, suggesting 
that rBAT plays a major role in HNF1β-triggered ROS 
resistance. These results strongly suggest that one of the 
primary roles of HNF1β is to avoid cellular oxidative 
stress and to enable cells to survive under stressful 
environments.
There are no reports indicating that HNF1β 
contributes to ROS resistance. However, Qadri et al. 
reported that HNF1 and HNF4 mediate hepatic multidrug 
resistance protein 2 up-regulation during hepatitis C 
virus gene expression, which may contribute to the 
cellular detoxification against ROS produced during HCV 
infection [68]. Wobser et al. reported that suppression of 
HNF-1 alpha results in mitochondrial dysfunction, cell 
apoptosis, and increased sensitivity to ceramide [69]. 
These data suggest that the HNF signal, as a whole, 
confers ROS resistance and anti-apoptotic effect. 
WHy does occc speciFically 
uNdertake uNique metabolic 
activity amoNg ovariaN caNcers?
The induction of HNF1β is reasonable in terms 
of the microenvironment with which these cells have to 
cope. As shown above, endometrioid epithelial cells are 
continuously exposed to severe oxidative stress caused by 
the contents of the cyst [10, 19]. Therefore, the primary 
requirement for survival of endometrial epithelial cells is 
the anti-stress capacity rather than proliferative potential. 
It is likely that HNF1β is induced for this purpose and 
its expression is maintained throughout malignant 
progression (Figure 2). HNF1β, as a transcription factor, 
induces multiple genes which participate in the Warburg 
effect, but other mechanisms also serve as tools to escape 
from intracellular stress. 
This is particularly important from a clinical point 
of view because the stress-resistant characteristic of 
OCCC may lead to the chemo-resistance as we report 
in this issue. Tamada et al. reported similar findings 
on CD44, a cell adhesion molecule, which interacted 
with pyruvate kinase M2 and enhances glycolysis [70]. 
Ablation of CD44 resulted in the reduction of GSH, the 
increase in intracellular ROS, and enhanced the effect of 
chemotherapeutic drugs. 
figure 2: Mechanism that occc cope with environmental oxidative stress. Oxidative stress induces a set of OCCC-specific 
genes, which we designated as the OCCC signature. HNF-1b, one of the most important transcriptional factors in the OCCC signature 
genes, suppresses cell growth on the one hand, and enhances survival mechanism by the metabolic reprogramming on the other hand. 
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HNF1β aNd subsequeNt metabolic 
AlterAtIons As possIble 
therApeutIc tArgets for occc
Currently, most of the cancer chemotherapies 
target cell proliferation. However, with growing evidence 
accumulating that indicates the importance of cancer-
specific metabolism, attempts to use modification of cancer 
metabolism as therapeutic target are also being focused 
[71, 72]. PI3K pathway, one of the most commonly 
activated signaling pathways in cancers including OCCC, 
has recently been implicated in glycolytic activity [73-
75]. Activated Akt signal was shown to stimulates aerobic 
glycolysis and maintain cell survival and resistance to 
apoptosis [31, 76]. It is assumed that oncogenes/tumor 
suppressor genes are more or less linked to the metabolic 
activity of cancer cells [30-34, 70, 71, 77]. Therefore, 
molecular target therapy against these signals might 
modulate intracellular metabolism toward anticancer 
effect [30, 78, 79]. 
More specific strategies to target metabolism itself 
are also being developed. PKM2, an isoform of PK, 
which catalyzes the conversion of phosphoenolpyruvate 
to pyruvate, is known to play a key role in glucose 
metabolism, and several small-molecule PKM2 
activators are being developed. Likewise, inhibitors 
of phosphoglycerate mutase 1 (PGAM1) and mutant 
isocitrate dehydrogenase (IDH), both catalases involved in 
glycolysis in cancer cells, are considered to be promising 
candidates as cancer drugs [80]. 
Because it has been reported that the Warburg effect 
as well as other metabolic alterations affect mitochondrial 
function, ROS production, and eventual apoptosis, each 
step involved in the oxidative phosphorylation is also a 
candidate target. It has been shown that suppression of 
glycolysis and shift to mitochondrial oxidation leads to 
cancer cell death [81]. 
Our study on the metabolic alterations caused 
by HNF1β in OCCC evokes some hints to disease 
management, as each step of clarified alterations could 
be candidate targets for treatment (Figure 3). First, we 
demonstrated that oxidative stress in the endometriotic cyst 
has causative relationship to OCCC [19]. Improvement of 
such microenvironment by surgical treatment may reduce 
the risk of cancer development. Second, we showed 
that HNF1β augments cell survival by enhancing ROS 
resistance in OCCC. HNF1β inhibition with some type 
of inhibitor, such as the microRNA mir-802 [82], may 
figure 3: potential therapeutic target for occc in terms of stress response. Primarily, improvement of stressful environment 
by the surgical intervention may lead to inhibition of cancer occurrence. In addition, interventions into each step of HNF-1β-related survival 
mechanism may provide more specific targeted therapy.
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have a therapeutic effect by abrogating ROS resistance. 
Third, our data indicated that HNF1β-induced cell survival 
is dependent on the glucose supply. HNF1β-high RMG2 
cells were more vulnerable to glucose deprivation. Several 
reports suggested that glucose deprivation is critical 
in cancers displaying the Warburg effect [72, 83, 84]. 
Therefore, glucose metabolism may be a therapeutic target 
in OCCC with high HNF1β expression. In ovarian cancer, 
metformin, an anti-diabetic drug, was shown to inhibit 
cancer growth and increase paclitaxel sensitivity in mouse 
model [85]. More specific reagents were also indicated 
to have anti-tumor effect by altering glycolytic activity 
[86-88] in vitro and in animal experiments. Tamada et al. 
showed that modulation of glucose metabolism by CD44 
contributes to the antioxidant status and drug resistance 
in cancer cells [70]. Human trial, especially from large 
studies, are not available yet, and to be evaluated in future. 
Finally, inhibition of GSH synthesis using reagents such 
as buthionine sulfoximine [89, 90], or inhibition of GSH 
synthesis by targeting the cystine transporter rBAT, may 
enhance the effect of conventional chemotherapy. 
conclusIons
Our studies along with others have started to explore 
the importance of cancer-specific metabolism in pursuing 
the cancer biology and also therapeutic application. 
Our serial studies suggest the possibility that cells 
maneuver their own metabolism to survive under stressful 
environments, and cancers that arise in such stressful 
conditions exhibit metabolic activity fine-tuned to resist 
intracellular stress, which may, in turn, leads to the drug 
resistance. 
Cancer specific metabolic activity could be a 
promising target as an individualized treatment in various 
cancers, and for this purpose, clarifying the features of 
metabolic activity in each cancer is needed. 
Abbreviations
HNF1β, hepatocyte nuclear factor 1β; OCCC, 
ovarian clear cell carcinoma; ROS, reactive oxygen 
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